Recently, TQB6457 for injection, a Class 1 innovative drug submitted by CTTQ Pharma, a core member company of Sino Biopharm (1177.HK), has officially received implied permission for clinical trials from the Center for Drug Evaluation (CDE), NMPA, for the treatment of advanced malignant neoplasms.

Recently, the results of the Phase II clinical trial (PACER-II) of TQC3721 suspension, a PDE3/4 inhibitor independently developed by CTTQ Pharma, a core member company of Sino Biopharm (1177.HK), for Chronic Obstructive Pulmonary Disease (COPD), were officially published in the renowned international respiratory journal CHEST.

On March 17, the 2026 Yabuli Entrepreneurs Forum was held in Yabuli, Heilongjiang. With the theme Confidence, Opportunity, and a New Chapter, the forum brought together entrepreneurs from all sectors to discuss new paths for development.

On March 14, the 2026 Shanghai Global Investment Promotion Conference opened with a main promotion event at the Shanghai East International Business Cooperation Zone.

On March 12, CTTQ Pharma, a core enterprise of Sino Biopharmaceutical Limited (1177.HK), announced that the Phase III clinical study of its independently developed Class 1 innovative drug, TQB3454 tablets, for the treatment of advanced bile duct cancer with IDH1 mutations, has completed its pre-specified interim analysis.

On March 9, the 2026 Forbes China list of Top 100 Outstanding Businesswomen was officially released, and the Chairwoman of the Board of Sino Biopharmaceutical Limited (1177.HK) was once again included for her profound influence in the field of pharmaceutical innovation.

On March 4, Sino Biopharmaceutical Limited (1177.HK) announced that it has reached an exclusive licensing agreement with Sanofi for Rovadicitinib, a novel, potent, first-in-class (FIC) oral small-molecule JAK/ROCK inhibitor.

On February 28, Rovadicitinib tablets (Anxu®, TQ05105), a Class 1 innovative drug from CTTQ Pharma, a core enterprise of Sino Biopharmaceutical Limited (1177.HK), was approved for marketing in China for the first-line treatment of adult patients with intermediate-2 or high-risk primary myelofibrosis (PMF), post-polycythaemia vera myelofibrosis (PPV-MF), or post-essential thrombocythaemia myelofibrosis (PET-MF).

On February 14, Benmelstobart Injection (Andewei®), a Class 1 new drug from CTTQ Pharma, a core enterprise of Sino Biopharmaceutical Limited (1177.HK), was approved by the National Medical Products Administration (NMPA). It is indicated for the treatment of patients with unresectable Stage III non-small cell lung cancer (NSCLC) who do not have known epidermal growth factor receptor (EGFR) sensitizing mutations or anaplastic lymphoma kinase (ALK) rearrangements and whose disease has not progressed following platinum-based concurrent or sequential radiochemotherapy.